SCHEMBL880503

SCHEMBL880503

CN(C)C(=O)N1CCC(NC(=O)OC(C)(C)C)CC1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CTSK P43235 2/20 0.52
HSD11B1 P28845 8/20 0.50
CYP2C9 P11712 1/20 0.50
EPHX1 P07099 1/20 0.50
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
NAMPT P43490 1/20 0.46
BTK Q06187 1/20 0.46
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MAPT P10636 1/20 0.43
KCNA3 P22001 1/20 0.43
PARP1 P09874 1/20 0.43
CKS1B P61024 1/20 0.42
SKP1 P63208 1/20 0.42
SKP2 Q13309 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30527730 0.91 HSD11B1 (0.57) CTSKHSD11B1CYP2C9EPHX1CA1
SCHEMBL31250358 0.91 HSD11B1 (0.57) CTSKHSD11B1CYP2C9EPHX1CA1
SCHEMBL6586590 0.89 DRD2 (0.49) CTSKHSD11B1CYP2C9EPHX1CA1
SCHEMBL4760650 0.85 CTSK (0.50) CTSKHSD11B1CYP2C9EPHX1CA1
SCHEMBL13666827 0.84 TSHR (0.57) CTSKHSD11B1CYP2C9EPHX1CA1
SCHEMBL89460 0.83 EPHX2 (0.56) CTSKHSD11B1CYP2C9EPHX1CA1
SCHEMBL6187601 0.83 CTSK (0.56) CTSKHSD11B1CYP2C9EPHX1CA1
SCHEMBL18926997 0.83 EPHX1 (0.70) CTSKHSD11B1CYP2C9EPHX1CA1
SCHEMBL27408850 0.83 CTSK (0.56) CTSKHSD11B1CYP2C9EPHX1CA1
SCHEMBL4760808 0.82 CTSK (0.50) CTSKHSD11B1CYP2C9EPHX1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8901315-B2 Thienopyrazole derivative having PDE7 inhibitory activity DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-12-02 US disclosed
US-8901315-B2 Thienopyrazole derivative having PDE7 inhibitory activity DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-12-02 US disclosed
US-20140073799-A1 THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-03-13 US disclosed
US-20140073799-A1 THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-03-13 US disclosed
EP-2433943-A1 Thienopyrazole derivatives having PDE7 inhibitory activity Daiichi Sankyo Company, Limited (JP) 2012-03-28 EP disclosed
US-20110166343-A1 THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-07-07 US disclosed
US-7932250-B2 Thienopyrazole derivative having PDE7 inhibitory activity DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-04-26 US disclosed
US-20090131413-A1 Thienopyrazole Derivative Having PDE7 Inhibitory Activity ASUBIO PHARMA CO., LTD. (JP) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140073799-A1 THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY PDE7A, PDE7B, PDE3B CTSK 2826/4885HSD11B1 311/4885CYP2C9 830/4885
US-20110166343-A1 THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY PDE7A, PDE7B, PDE3B CTSK 2826/4885HSD11B1 311/4885CYP2C9 830/4885
US-20090131413-A1 Thienopyrazole Derivative Having PDE7 Inhibitory Activity PDE7A, PDE7B, PDE3B CTSK 2826/4885HSD11B1 311/4885CYP2C9 830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.